Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice

Shanthadevi Udayappan, Louise Manneras-Holm, Alice Chaplin-Scott, Clara Belzer, Hilde Herrema, Geesje M Dallinga-Thie, Erik S G Stroes, Albert K Groen, Harry J Flint, Fredrik Backhed, Willem M de Vos, Max Nieuwdorp, Sylvia Helen Duncan

Research output: Contribution to journalArticlepeer-review

108 Citations (Scopus)
5 Downloads (Pure)


An altered intestinal microbiota composition is associated with insulin resistance and type 2 diabetes mellitus. We previously identified increased intestinal levels of Eubacterium hallii, an anaerobic bacterium belonging to the butyrate-producing Lachnospiraceae family, in metabolic syndrome subjects who received a faecal transplant from a lean donor. To further assess the effects of E. hallii on insulin sensitivity, we orally treated obese and diabetic db/db mice with alive E. hallii and glycerol or heat-inactive E. hallii as control. Insulin tolerance tests and hyperinsulinemic-euglycemic clamp experiments revealed that alive E. hallii treatment improved insulin sensitivity compared control treatment. In addition, E. hallii treatment increased energy expenditure in db/db mice. Active E. hallii treatment was found to increase faecal butyrate concentrations and to modify bile acid metabolism compared with heat-inactivated controls. Our data suggest that E. hallii administration potentially alters the function of the intestinal microbiome and that microbial metabolites may contribute to the improved metabolic phenotype.

Original languageEnglish
Article number16009
JournalNPJ biofilms and microbiomes
Publication statusPublished - 6 Jul 2016


  • Journal Article


Dive into the research topics of 'Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice'. Together they form a unique fingerprint.

Cite this